PE20090225A1 - Proteinas de fusion que degradan el peptido beta amiloide - Google Patents
Proteinas de fusion que degradan el peptido beta amiloideInfo
- Publication number
- PE20090225A1 PE20090225A1 PE2008000557A PE2008000557A PE20090225A1 PE 20090225 A1 PE20090225 A1 PE 20090225A1 PE 2008000557 A PE2008000557 A PE 2008000557A PE 2008000557 A PE2008000557 A PE 2008000557A PE 20090225 A1 PE20090225 A1 PE 20090225A1
- Authority
- PE
- Peru
- Prior art keywords
- fusion proteins
- amyloid peptide
- beta amyloid
- fusion protein
- peptide
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
- 230000000593 degrading effect Effects 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 235000004252 protein component Nutrition 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
REFERIDA A UNA PROTEINA DE FUSION DE FORMULA M-A, DONDE M ES UN COMPONENTE PROTEICO QUE PROLONGA LA VIDA MEDIA DE LA PROTEINA DE FUSION TAL COMO UNA PARTE Fc DE UN ANTICUERPO IgG2 Y A ES UN COMPONENTE PROTEICO QUE CORTA EL PEPTIDO BETA AMILOIDE TAL COMO NEPRILISINA EXTRACELULAR QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID N 1,2,3 O 4 Y DONDE DICHOS M Y A ESTAN UNIDOS POR UN CONECTOR L TAL COMO UN PEPTIDO O UN CONECTOR QUIMICO. DICHA PROTEINA DE FUSION CORTA EL PEPTIDO BETA AMILOIDE Y ES UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90847107P | 2007-03-28 | 2007-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090225A1 true PE20090225A1 (es) | 2009-04-19 |
Family
ID=39788753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000557A PE20090225A1 (es) | 2007-03-28 | 2008-03-27 | Proteinas de fusion que degradan el peptido beta amiloide |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080242590A1 (es) |
| EP (1) | EP2139525A4 (es) |
| JP (1) | JP2010522559A (es) |
| CN (1) | CN101668545A (es) |
| AR (1) | AR066199A1 (es) |
| AU (1) | AU2008230177B2 (es) |
| CA (1) | CA2681404A1 (es) |
| CL (1) | CL2008000910A1 (es) |
| PE (1) | PE20090225A1 (es) |
| TW (1) | TW200907056A (es) |
| UY (1) | UY30984A1 (es) |
| WO (1) | WO2008118093A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012530498A (ja) * | 2009-06-19 | 2012-12-06 | メディミューン，エルエルシー | プロテアーゼバリアント |
| WO2011160732A1 (en) | 2010-06-21 | 2011-12-29 | Medimmune, Llc. | Protease variants of human neprilysin |
| WO2011161127A1 (en) | 2010-06-21 | 2011-12-29 | Medimmune, Llc | Protease variants of human neprilysin |
| WO2012145428A2 (en) * | 2011-04-21 | 2012-10-26 | Washington University | Altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid |
| CN103529182B (zh) * | 2012-07-06 | 2016-03-16 | 中国科学院上海生命科学研究院 | rbo/Efr3a/Efr3b基因或其蛋白在诊断和治疗阿尔茨海默病中的应用 |
| EP2832854A1 (en) * | 2013-08-02 | 2015-02-04 | F. Hoffmann-La Roche AG | Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin |
| KR20160037173A (ko) * | 2013-08-02 | 2016-04-05 | 에프. 호프만-라 로슈 아게 | 치료학적 융합 단백질 |
| CN106574930B (zh) * | 2014-05-22 | 2019-09-03 | 株式会社岛津制作所 | 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法 |
| KR20180133463A (ko) * | 2016-04-14 | 2018-12-14 | 타오 헬스 라이프 파마 가부시키가이샤 | 아밀로스페로이드(aspd) 결합 저해 펩타이드, 및 평가 및 스크리닝 방법 |
| AU2018212860A1 (en) * | 2017-01-30 | 2019-08-15 | National Research Council Of Canada | Blood-brain barrier transmigrating compounds and uses thereof |
| WO2018174668A2 (ko) | 2017-03-23 | 2018-09-27 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 |
| CN110241128B (zh) * | 2018-03-07 | 2020-10-02 | 上海大学 | 一种含有cbd的融合基因、细胞系、液态ecm与应用 |
| EP3826649A4 (en) | 2018-07-23 | 2022-07-20 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
| AU2019310040A1 (en) | 2018-07-23 | 2021-02-11 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
| KR20220011123A (ko) | 2019-04-11 | 2022-01-27 | 엔클리어 테라피스, 인크. | 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템 |
| US12337140B2 (en) | 2020-09-29 | 2025-06-24 | Enclear Therapies, Inc. | Subarachnoid fluid management method and system with varying rates |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| PL199659B1 (pl) * | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
| US20020086405A1 (en) * | 2000-09-25 | 2002-07-04 | Inmaculada Silos-Santiago | 56638, a novel human neprilysin protease and uses thereof |
| CA2260376A1 (en) * | 1999-02-11 | 2000-08-11 | Universite De Montreal | New metalloproteases of the neprilysin family |
| US20030083277A1 (en) * | 2000-02-24 | 2003-05-01 | Hersh Louis B. | Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients |
| WO2002096460A1 (en) * | 2001-05-30 | 2002-12-05 | Cornell Research Foundation, Inc. | Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer |
| US20050118632A1 (en) * | 2003-11-06 | 2005-06-02 | Jian Chen | Polynucleotides and polypeptides encoding a novel metalloprotease, Protease-40b |
| JP2009509564A (ja) * | 2005-10-03 | 2009-03-12 | アストラゼネカ・アクチエボラーグ | 血漿中半減期が調節された融合タンパク質 |
-
2008
- 2008-03-26 TW TW097110852A patent/TW200907056A/zh unknown
- 2008-03-27 CN CN200880010294A patent/CN101668545A/zh active Pending
- 2008-03-27 AR ARP080101265A patent/AR066199A1/es not_active Application Discontinuation
- 2008-03-27 CA CA002681404A patent/CA2681404A1/en not_active Abandoned
- 2008-03-27 JP JP2010500877A patent/JP2010522559A/ja not_active Withdrawn
- 2008-03-27 AU AU2008230177A patent/AU2008230177B2/en not_active Ceased
- 2008-03-27 UY UY30984A patent/UY30984A1/es not_active Application Discontinuation
- 2008-03-27 PE PE2008000557A patent/PE20090225A1/es not_active Application Discontinuation
- 2008-03-27 EP EP08741880A patent/EP2139525A4/en not_active Withdrawn
- 2008-03-27 WO PCT/SE2008/050346 patent/WO2008118093A1/en not_active Ceased
- 2008-03-28 US US12/057,464 patent/US20080242590A1/en not_active Abandoned
- 2008-03-28 CL CL2008000910A patent/CL2008000910A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008118093A1 (en) | 2008-10-02 |
| JP2010522559A (ja) | 2010-07-08 |
| CN101668545A (zh) | 2010-03-10 |
| AR066199A1 (es) | 2009-08-05 |
| AU2008230177A1 (en) | 2008-10-02 |
| CL2008000910A1 (es) | 2008-11-21 |
| TW200907056A (en) | 2009-02-16 |
| EP2139525A4 (en) | 2010-08-18 |
| CA2681404A1 (en) | 2008-10-02 |
| EP2139525A1 (en) | 2010-01-06 |
| US20080242590A1 (en) | 2008-10-02 |
| UY30984A1 (es) | 2008-10-31 |
| AU2008230177B2 (en) | 2012-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090225A1 (es) | Proteinas de fusion que degradan el peptido beta amiloide | |
| Haney et al. | Peptide design for antimicrobial and immunomodulatory applications | |
| UY31123A1 (es) | Proteinas de fusion natriureticas | |
| IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
| EA201590545A1 (ru) | Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией | |
| EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
| PE20131334A1 (es) | Anticuerpo igg1 humanizado | |
| DK1761553T3 (da) | MHC molecule-binding tumor-associated peptides | |
| ATE527353T1 (de) | Pdgf-bindendes polypeptid aus protein a | |
| NO20063026L (no) | Antistoffer | |
| HK1200842A1 (en) | Proteins with improved half-life and other properties | |
| PE20171325A1 (es) | Polipeptidos del receptor de activina variante y uso de los mismos | |
| PA8738401A1 (es) | Proteinas de fusion de exendina | |
| PE20090711A1 (es) | Region constante de anticuerpo mutante | |
| MX2014005108A (es) | Constructos de polipeptidos y sus usos. | |
| NO20071419L (no) | Polypeptidvarianter med endret effektorfunksjon | |
| UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
| PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| EA201390820A1 (ru) | Слитый белок против рака | |
| UA102061C2 (ru) | Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний | |
| DE602005008996D1 (de) | Radiofluorierte peptide | |
| PL393578A1 (pl) | Przeciwnowotworowe białko fuzyjne | |
| EA200901441A1 (ru) | Новые молекулы антител и нуклеиновых кислот, связывающиеся с грибным белком теплового шока hsp90 | |
| EA200700973A1 (ru) | Слитый белок, содержащий домен bh3 белка «вh3-только» | |
| DK2007885T3 (da) | Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |